In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Roche acquires Cetus PCR rights for $300M plus $30M royalties

Executive Summary

Hoffmann-La Roche (US subsidiary of Roche Holdings) has acquired full rights to the Polymerase Chain Reactor (PCR) technology from the Cetus Corporation. Hoffmann-La Roche will pay a cash value of $300 million and royalties of up to $30 million.
Deal Industry
  • Biotechnology
  • In Vitro Diagnostics
  • In Vitro Diagnostics
    • Molecular Diagnostics & Genetic Testing
Deal Status
  • Final
Deal Type
  • Alliance
    • Product Purchase

Related Companies